Patents by Inventor Colin Roger Mackenzie

Colin Roger Mackenzie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AXL-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20240076389
    Abstract: AXL-specific antibodies and uses therefor are described, including monoclonal and single domain antibodies. Such antibodies bind to cell surface expressed human AXL at an epitope in an immunoglobulin-like (IgL) domain of the AXL ectodomain. The antibody may be used in an antibody-drug conjugate (ADC), for example in the treatment, detection or staging of cancer. The antibody may be biparatopic.
    Type: Application
    Filed: June 27, 2023
    Publication date: March 7, 2024
    Applicant: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Kevin HENRY, Maria Luz JARAMILLO, Colin Roger MACKENZIE, Anne MARCIL
  • AXL-specific antibodies and uses thereof
    Patent number: 11739154
    Abstract: AXL-specific antibodies and uses therefor are described, including monoclonal and single domain antibodies. Such antibodies bind to cell surface expressed human AXL at an epitope in an immunoglobulin-like (IgL) domain of the AXL ectodomain. The antibody may be used in an antibody-drug conjugate (ADC), for example in the treatment, detection or staging of cancer. The antibody may be biparatopic.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: August 29, 2023
    Assignee: NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Kevin Henry, Maria Luz Jaramillo, Colin Roger Mackenzie, Anne Marcil
  • AXL-SPECIFIC ANTIBODIES AND USES THEREOF
    Publication number: 20200277386
    Abstract: AXL-specific antibodies and uses therefor are described, including monoclonal and single domain antibodies. Such antibodies bind to cell surface expressed human AXL at an epitope in an immunoglobulin-like (IgL) domain of the AXL ectodomain. The antibody may be used in an antibody-drug conjugate (ADC), for example in the treatment, detection or staging of cancer. The antibody may be biparatopic.
    Type: Application
    Filed: September 10, 2018
    Publication date: September 3, 2020
    Inventors: Kevin HENRY, Maria Luz JARAMILLO, Colin Roger MACKENZIE, Anne MARCIL
  • Anticarcinoma antibodies and uses thereof
    Patent number: 7872105
    Abstract: A novel single domain antibody AFAI and fragments thereof which has specific affinity for binding to carcinoma, and especially lung carcinoma. This antibody, and portions thereof, can be used, inter alia in the diagnosis and treatment of carcinoma.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: January 18, 2011
    Assignees: National Research Council of Canada, Ottawa Hospital Research Institute
    Inventors: Colin Roger Mackenzie, Jianbing Zhang, Thanh-Dung Nguyen, Qinggang Li, Kien Trung Mai
  • Modified aerolysin and methods of use for treating lung cancer
    Publication number: 20090226942
    Abstract: Disclosed herein are lung cancer specific binding agents, as well as related amino acid and nucleic acid sequences. Methods of using such agents in the diagnosis and treatment of treat lung cancer are also disclosed. In an embodiment of the invention there is provided an antibody or fragment thereof comprising the sequence Ser Gly Asn Gly Gly Thr in the region corresponding to the CDR 2.
    Type: Application
    Filed: March 27, 2008
    Publication date: September 10, 2009
    Inventors: Colin Roger MacKenzie, Qinggang Li, Jianbing Zhang